ETView Ltd

Proud of Trendlines portfolio co @vivasight ETView Reaches 2nd Distribution Agreement in China trendlines.com/etview-reaches… @bill_edelman

FDA releases final guidance on reprocessing of reusable medical devices. fda.gov/NewsEvents/New…

"New superbug outbreak tied to endoscope devices surfaces amid FDA scrutiny" read more: fiercemedicaldevices.com/story/new-supe…

New Prospective, Randomized, Comparative study shows outstanding results for Vivasight. link.springer.com/article/10.100…

The FDA is warning about the use of endoscopes following a superbug outbreak, effecting 179 people, killing two. reuters.com/article/2015/0…

Great article by @anesthesianews which features @vivasight for the first time! p3-medical.com/UK/News/Advanc… #anaesthesia #RCoANews

Join us for an exciting lecture at ASA 2014, by J.H. Campus (MD).

Join us at ICISA, Tel Aviv, Israel, September 16-18, booth 16.

Just approved by the regulatory authorities: Vivasight-DL now has an extended shelf life of 5 years !

WSJ picked up our recent report on Vivasight-DL clinical trials. read about it at: online.wsj.com/article/PR-CO-…

We are proud to report on our successful first participation at ESA congress, Stockholm. read more at etview.com/may-31-2-june-…

New clinical data from Haga university hospital (Holland), shows 17.2% to 51.6% cost savings for OLV with Vivasight-DL Vs standard DLT.

New clinical paper from MD Anderson, Texas, shows that Vivasight-DL does not require the use of a bronchoscope in 93.2% of cases !

ETView signs a distribution agreement with Technolab (Ecuador) and Medcare (Austria) etview.com/news-and-events